Souhaitez-vous accéder aux communiqués récents ?
Créez un compte lecteur dès aujourd’hui afin de suivre les secteurs et les entreprises qui vous intéressent, et configurer votre tableau de bord.
-
Immuneering to Announce 12-Month Overall Survival Data from Phase 2a Clinical Trial of Atebimetinib + mGnP in First-Line Pancreatic Cancer Patients on Janu
-
- Announced extraordinary 86% overall survival at 9 months in first-line pancreatic cancer patients treated with atebimetinib + mGnP - - Raised $225 million of financing, including $25 million...
-
- New case studies on first-line pancreatic cancer patients treated with atebimetinib in combination with FOLFIRINOX to be shared by trial investigators – - Conference call scheduled for Wednesday,...
-
NEW YORK, Sept. 26, 2025 (GLOBE NEWSWIRE) -- Immuneering Corporation (Nasdaq: IMRX), a clinical-stage oncology company focused on keeping cancer patients alive, today announced that it will host a...
-
Immuneering Appoints Dr. Thomas Schall as Chairman of the Board
-
Immuneering Announces Closing of $25 Million Private Placement
-
Immuneering Announces Clinical Supply Agreement with Lilly to Evaluate Atebimetinib in Combination with Olomorasib
-
Immuneering Announces $25 Million Private Placement
-
Immuneering Reports Second Quarter 2025 Financial Results and Provides Business Updates
-
Immuneering to Present at the 24th Annual Needham Virtual Healthcare Conference